- Home
- TDC vs DNLI Comparison
TDC vs DNLI Comparison
Compare TDC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDC
- DNLI
- Stock Information
- Founded
- TDC 1979
- DNLI 2013
- Country
- TDC United States
- DNLI United States
- Employees
- TDC N/A
- DNLI N/A
- Industry
- TDC Computer Software: Prepackaged Software
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TDC Technology
- DNLI Health Care
- Exchange
- TDC Nasdaq
- DNLI Nasdaq
- Market Cap
- TDC 2.3B
- DNLI 2.1B
- IPO Year
- TDC 2007
- DNLI 2017
- Fundamental
- Price
- TDC $22.97
- DNLI $14.78
- Analyst Decision
- TDC Hold
- DNLI Strong Buy
- Analyst Count
- TDC 10
- DNLI 16
- Target Price
- TDC $31.56
- DNLI $37.57
- AVG Volume (30 Days)
- TDC 2.5M
- DNLI 1.3M
- Earning Date
- TDC 05-05-2025
- DNLI 05-06-2025
- Dividend Yield
- TDC N/A
- DNLI N/A
- EPS Growth
- TDC 90.16
- DNLI N/A
- EPS
- TDC 1.16
- DNLI N/A
- Revenue
- TDC $1,750,000,000.00
- DNLI N/A
- Revenue This Year
- TDC N/A
- DNLI N/A
- Revenue Next Year
- TDC $0.18
- DNLI $497.02
- P/E Ratio
- TDC $19.81
- DNLI N/A
- Revenue Growth
- TDC N/A
- DNLI N/A
- 52 Week Low
- TDC $21.80
- DNLI $13.67
- 52 Week High
- TDC $39.12
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- TDC 39.64
- DNLI 39.87
- Support Level
- TDC $22.52
- DNLI $13.67
- Resistance Level
- TDC $24.40
- DNLI $14.90
- Average True Range (ATR)
- TDC 0.62
- DNLI 0.76
- MACD
- TDC 0.31
- DNLI 0.15
- Stochastic Oscillator
- TDC 45.00
- DNLI 42.53
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.